More than 25 transactions across five continents

Twenty-two completed transactions can be described publicly: mergers and acquisitions of sites and entities, licences granted and acquired, joint ventures, technology transfers, strategic alliances and divestitures of products. Led, negotiated and closed in Asia, Europe, the Americas, the Middle East and Africa.

Asia, where the edge is

Commercial joint ventures in Japan generating more than one hundred million euros in sales. A flu-pandemic manufacturing partnership delivering more than ten million euros of annual net profit. A reshaping of the industrial and commercial footprint in Asia worth more than three hundred million pounds in considerations and savings. Partnerships in Korea, Malaysia and India, including one with an Indian blue chip to secure affordable malaria vaccine supply.

Europe, the Americas, the Middle East and Africa

Growth of the public vaccine business in Brazil. Covid-19 pandemic vaccine development agreements. A worldwide partnership network built across Egypt, Saudi Arabia, Morocco, Korea, Turkey, Malaysia and Russia. Winding up of a commercial joint venture in Japan and of a research joint venture in Singapore.

Both sides of the table

The list matters less than the fact that these transactions were run from both sides: as a buyer and as a seller, as a licensor and as a licensee. What a counterparty is about to argue is rarely a surprise.